Six months on Wegovy: what NHS patients can actually expect

What did @jessstebb actually say?

Jess shared a six-month Wegovy update filmed before an NHS weight management appointment in Edinburgh. The key clinical detail: she had been on the 1.7mg semaglutide dose for three months, deliberately pausing her dose escalation because her IBS was reacting badly. She said she wanted to "let my body... do this thing" before moving up. She also confirmed she had lost weight, though the transcript cuts off before the exact figure is clear.

This is a pretty common scenario for real-world Wegovy users, and it's worth examining whether her approach to dose-holding was sensible, what the science says about GI side effects and IBS, and what the NHS dose schedule actually looks like.

Does the science back this up?

Yes, broadly. Pausing dose escalation when GI side effects are significant is not just acceptable, it is actively recommended in clinical guidance. The SUSTAIN trial programme and the STEP trials both reported that nausea, vomiting and diarrhoea are the most common reasons participants reduce or delay semaglutide escalation, with GI adverse events affecting around 44% of participants in STEP 1 (Wilding et al., 2021, NEJM).

For people with pre-existing IBS, the picture is more complicated. Semaglutide slows gastric emptying and alters gut motility, which can worsen IBS symptoms in some patients. A 2022 review by Grover and colleagues in Neurogastroenterology and Motility noted that GLP-1 receptor agonists modulate the gut-brain axis in ways that are not fully understood, and that patients with functional gut disorders may experience amplified GI effects. The 1.7mg dose sits between the 1.0mg and 2.4mg maintenance doses on the standard Wegovy escalation schedule, so holding at that level for three months is within the range of what clinicians do in practice.

What did they get wrong (or right)?

Jess gets credit here. She did not push through side effects to chase faster results, which is genuinely the smarter move. There is a real tendency in weight loss content to frame GI distress as something to just tolerate, but that is not what the clinical evidence supports. The STEP 1 trial showed that slower titration was associated with better tolerability without meaningfully compromising long-term weight loss outcomes.

One small inaccuracy worth flagging: Jess refers to the medication as "my goby" throughout, which is clearly just a pronunciation shorthand, not a clinical error. More substantively, she does not clarify whether her 1.7mg hold was clinician-directed or self-directed. That distinction matters. Adjusting your own dose schedule without clinical oversight is not something this fact-check endorses, and the NHS weight management pathway she references does involve clinical supervision, so it is worth noting that patients should always discuss dose changes with their prescriber.

What should you actually know?

Wegovy's standard UK escalation schedule runs from 0.25mg weekly for four weeks, stepping up to 0.5mg, 1.0mg, 1.7mg, and finally 2.4mg as the maintenance dose. Holding at any step is a recognised clinical option when side effects are significant. The 2.4mg dose delivered around 15% average body weight loss at 68 weeks in STEP 1, but individual responses vary considerably.

For IBS specifically, the evidence on GLP-1 receptor agonists is mixed. Some patients with IBS-C (constipation-predominant) may actually see symptom improvement due to increased gut motility, while IBS-D (diarrhoea-predominant) patients are more likely to experience worsening. If you have IBS and are on or considering semaglutide, that distinction is worth raising with your prescriber before starting, not after you are already three months into a dose hold.

• Do not adjust your Wegovy dose schedule without speaking to your prescriber first.
• GI side effects are common but usually improve over time with dose stabilisation.
• NHS weight management programmes include clinical oversight, which is the appropriate setting for these decisions.